FREMONT, Calif. — Neuralink's brain-computer interface program is scaling faster than ever, with the company now reporting its 26th human implant recipient — up from 21 participants confirmed globally at the start of 2026 — as its clinical trials expand across three continents.
The milestone underscores how quickly Elon Musk's neurotechnology venture is moving from one-off surgical firsts to a repeatable clinical program. Each new patient adds data that sharpens the device's decoding algorithms, reflecting the same industrial-scale ambition that runs through Musk's other ventures, from modular AI data centers at Tesla to reusable rockets at SpaceX.
Two Studies, Three Countries
Neuralink's trials now span two flagship programs. The PRIME Study targets people with quadriplegia from spinal-cord injury or ALS, giving them the ability to control computers and robotic arms through thought alone. The VOICE trial focuses on decoding intended speech for individuals with severe speech impairment, translating neural signals into words.
The company has also gone international, launching studies in the United Arab Emirates, the United Kingdom, and Canada. As of May, seven patients were enrolled in the GB PRIME study in Great Britain — a global footprint that echoes the reach of Musk's broader technology empire, including SpaceX's plan to build an orbital AI constellation called Starmind.
The Technology Inside
At the heart of each procedure is the Link, an implant roughly the size of a quarter — about 23 millimeters across — packing up to 3,072 electrodes that read activity from individual neurons. Ultrafine threads are placed into the brain by a purpose-built surgical robot with a precision no human hand can match.
Regulators have taken notice. Neuralink has secured FDA Breakthrough Device Designation for both its speech-restoration technology and Blindsight, its project aimed at restoring a form of vision to people who have lost their sight. The designation is reserved for technologies that could offer meaningful advantages over existing treatments for serious conditions, and it streamlines the path to review.
Toward High-Volume Production
Musk has said Neuralink intends to begin high-volume production this year and move to a streamlined, almost entirely automated surgical procedure, with device threads passing through the brain's protective dura without the need to remove it — a change he has called "a big deal" for both speed and safety.
For the patients at the center of it all, the progress is deeply personal: people who could not move or speak are once again controlling cursors, playing games, and communicating. With its trial roster growing and regulators leaning in, Neuralink appears to be closing the gap between a remarkable research project and a therapy that could reach thousands. More detail on each participant's journey is shared through the company's own updates page.
